The FDA understands that there is increasing interest in the potential utility of cannabis for a variety of medical conditions, as well as research on the potential adverse health effects from use of cannabis. To date, the FDA has not…

From innovative leaps in cancer diagnosis and treatment to the growing force of artificial intelligence in aiding medical discovery, the 2010s was a ground-breaking decade for the life science industry. We have seen the steady rise of…

From innovative leaps in cancer diagnosis and treatment to the growing force of artificial intelligence in aiding medical discovery, the 2010s was a ground-breaking decade for the life science industry. We have seen the steady rise of…

In its continuous endeavor to bolster the competitiveness of the generics market, the US Food and Drug Administration (FDA) updated its list of ‘off-patent, off-exclusivity drugs without an approved generic’. This update is part of FDA’s…

The US Food and Drug Administration (FDA) has released draft guidance for public consultation on the use of the Inactive Ingredient Database (IID). The document is intended to provide information on how to use the IID when choosing inactive…

A BioPharma Dive article The Food and Drug Administration's top drug regulator sharply criticized the current clinical trial regime, calling for industry to embrace more collaborative studies. "I believe the clinical trial system is…

12. August 2018 The FDA recently revamped the methods it uses to determine which foreign and domestic drug manufacturing sites warrant inspection or other types of surveillance and at what frequency. In…

14. January 2018 Data integrity continued to be a hot topic in the pharmaceutical industry through 2017. According to a recent analysis by GMP (good manufacturing practices)…

29. January 2018 (Reuters) - The head of the U.S. Food and Drug Administration on Thursday said it is preparing a new, more restrictive policy targeting what drugs compounding pharmacies can produce that do not…